4.7 Article

Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia

期刊

BLOOD
卷 112, 期 10, 页码 4178-4183

出版社

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2008-06-165027

关键词

-

资金

  1. National Cancer Institute (NCI) [SPEC U01 CA114762]
  2. Penelope London Foundation
  3. Friedman Fund for Childhood Leukemia
  4. Walter Family Pediatric Leukemia Fund
  5. Pediatric Cancer Foundation [CA093552-02, NCI CA 51 001, CA 78 224, CA21765]
  6. National Institutes of Health (NIH)/National Institute of General Medical Sciences Pharmacogenetics Research Network and Database [U01 GM61393, U01GM61374]
  7. NIH
  8. American Lebanese Syrian Associated Charities
  9. CureSearch

向作者/读者索取更多资源

The underlying pathways that lead to relapse in childhood acute lymphoblastic leukemia (ALL) are unknown. To comprehensively characterize the molecular evolution of relapsed childhood B-precursor ALL, we used human 500K single-nucleotide polymorphism arrays to identify somatic copy number alterations (CNAs) in 20 diagnosis/relapse pairs relative to germ line. We identified 758 CNAs, 66.4% of which were less than 1 Mb, and deletions outnumbered amplifications by approximately 2.5:1. Although CNAs persisting from diagnosis to relapse were observed in all 20 cases, 17 patients exhibited differential CNA patterns from diagnosis to relapse. Of the 396 CNAs observed in 20 relapse samples, only 69 (17.4%) were novel ( absent in the matched diagnosis samples). EBF1 and IKZF1 deletions were particularly frequent in this relapsed ALL cohort (25.0% and 35.0%, respectively), suggesting their role in disease recurrence. In addition, we noted concordance in global gene expression and DNA copy number changes (P = 2.2 x 10(-16)). Finally,relapse-specific focal deletion of MSH6 and, consequently, reduced gene expression were found in 2 of 20 cases. In an independent cohort of children with ALL, reduced expression of MSH6 was associated with resistance to mercaptopurine and prednisone, thereby providing a plausible mechanism by which this acquired deletion contributes to drug resistance at relapse. (Blood. 2008; 112: 4178-4183)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据